We’ve rebranded some of our products, learn more ›

CODEX® is now PhenoCycler,
Phenoptics™ is now Phenolmager.

Advancing Spatial Biology to the Clinic: The Power of Multiplex Immunofluorescence-based Biomarkers for Companion Diagnostics

Webinar | Monday, June 10, 2024
This webinar aims to provide insights into immunofluorescence-based biomarker analysis with key considerations for developing a companion diagnostic (CDx). These include avoiding common pitfalls associated with multiplex immunofluorescence and multispectral imaging, and successfully harnessing its full potential in the clinical setting. 
 
Recently, there have been many advancements in examining biomarker expression and heterogeneity within the tumor microenvironment using high-throughput technologies. However, current clinical tests for biomarkers often fall short in providing sufficient information to effectively predict treatment response. 
  
Multiplex fluorescence immunohistochemistry and image data analysis have helped uncover meaningful spatial relationships between specific biomarkers, offering valuable insights into patient responses to immune checkpoint inhibitors, antibody-drug conjugates (ADCs) and DNA damage response (DDR) targeted therapies. These techniques have become indispensable for gathering critical data from clinical programs. 
 
Multiplex fluorescence immunohistochemistry and image data analysis have helped uncover meaningful spatial relationships between specific biomarkers, offering valuable insights into patient responses to immune checkpoint inhibitors, antibody-drug conjugates (ADCs) and DNA damage response (DDR) targeted therapies. These techniques have become indispensable for gathering critical data from clinical programs. 
  
As multiplex immunofluorescence techniques mature as an analytical platform, it is important to understand the technology’s fundamentals and its application in assessing response for both mono- and combination therapies. 

Video

bbe8f2547285e5791ed9eacb73a4903b

Speakers

Mark Lander

Mark Landers

Vice President, Precision Medicine

Mark Landers is Vice President of Precision Medicine at Akoya Biosciences and has over 25 years’ experience in oncology diagnostics. Prior to joining Akoya, Mark held leadership positions at Exact Sciences, Guardant Health and Epic Sciences focused on driving precision medicine with pharma partners. Leveraging a strong technical background from years in R&D, he has successfully brought multiple diagnostic tests and companion diagnostics to market.

Pascal Bamford

Pascal Bamford, PhD

Senior Vice President, R&D and Laboratory Operations, Akoya Biosciences

Pascal joined Akoya Biosciences in October 2021 in the role of Senior Vice President, Research and Development and Laboratory Operations. He possesses deep scientific and operational experience leading teams in developing and implementing successful and innovative products through international regulatory agencies to customers and patients worldwide. Prior to joining Akoya, he served as Senior Vice President of Products and Services Research and Development at Exact Sciences and has previously held leadership positions at Epic Sciences, Ventana Medical Systems, and Monogen. Pascal earned a PhD in cell image analysis from the University of Queensland, Australia, and a master’s degree in engineering from the University of Bristol, UK, and Ecole Nationale Supérieure des Télécommunications, France.